Cas:105612-78-0 Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate manufacturer & supplier

Chemical Name:Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate

CAS.NO:105612-78-0

Synonyms:Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate

Molecular Formula:C₉H₉BrN₂O₅

Molecular Weight:305.08200

HS Code:2909309090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:94.24000

Exact Mass:303.96900

LogP:2.21740

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate Use and application,Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate technical grade,usp/ep/jp grade.

Related News: A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate manufacturer The Department of Health and Human Services asked the Defense Department to provide several facilities capable of housing at least 250 people in individual rooms through to February 29, the Pentagon said. Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate supplier A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate vendor In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum. Ethyl [(5-bromo-3-nitro-2-pyridinyl)oxy]acetate factory In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.